China Life Private Equity Investment and PICC Capital returned to co-lead the pharmaceutical discovery technology provider’s latest rounds, four months after it emerged from stealth.
US-based drug discovery platform developer Metis Therapeutics announced $150m in funding on Wednesday across two rounds co-led by insurers China Life Insurance and People’s Insurance Company of China.
Sequoia Capial China, 5Y Capital, CMB International, Lightspeed China Partners, Monolith and FreesFund also took part in the rounds. The lead investors were represented by China Life Private Equity Investment and PICC Capital respectively.
Metis is developing an artificial intelligence (AI) and data-driven software platform that helps users carry out molecular dynamics…
